Management and Diagnosis of Empagliflozin-Induced Burning Mouth Syndrome: A Case Report

Burning mouth syndrome (BMS) poses a significant clinical challenge. Patients often present with symptoms that can severely affect their quality of life, leading to anxiety, depression, and social withdrawal. The etiology of BMS remains poorly understood, which complicates its diagnosis and treatment. This case report describes an 80-year-old woman who presented with BMS following the administration of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for glycemic control, along with its benefits in the progression and prognosis of cardiac insufficiency and chronic renal disease. Despite multiple treatments, her symptoms persisted until empagliflozin withdrawal, resulting in significant improvement at the six-month follow-up. This report suggests a potential association between empagliflozin and BMS, underscoring the need for clinicians to be vigilant regarding drug-related etiologies in the diagnosis and management of oral symptoms.